3D printed drug delivery devices: recent promises and challenges

3D printing (3DP) has gained decent pace in the past decade in the pharmaceutical and biomedical fields. The approval of 3D-printed medical devices has gained more attraction than that of 3D-printed drug products. However, concerns related to cost-effectiveness, efficacy, and large-scale manufacturing are still prevalent, thus challenging the mainstream development of 3D-printed drug delivery devices.

Drug delivery devices and scaffolds, along with the possibilities involving artificial intelligence (AI), machine learning (ML), and automation, for personalized applications. The regulatory guidelines, as well as a glimpse of drug delivery devices under clinical trials, are discussed.

Although 3DP offers patient-tailored, on-demand products, its clinical adoption is hindered by regulatory barriers, limited standards, and scalability issues. Integrating AI/ML could offer real-time adaptive clinical manufacturing; however, the guidelines for these disruptive technologies are often unclear. With patient-centric manufacturing, 3D-printed devices and scaffolds could play a key role in personalized medicine, delivering targeted and effective therapies.The transition from proof-of-concept to real-world testing underscores the growing feasibility and clinical relevance of 3DP technologies. With rapid progress in bio-responsive materials and AI-driven design tools, 3D-printed delivery platforms are expected to improve in adaptability and therapeutic effectiveness for next-generation personalized therapies.